Core Insights - Indivior PLC is recognized as one of the best performing healthcare stocks, specializing in treatments for opioid use disorder (OUD) with key products SUBLOCADE and SUBOXONE [1] Financial Performance - In Q2 2025, Indivior reported total net revenue of $302 million, with SUBLOCADE sales increasing by 9% year-over-year to $209 million, driven by a 20% rise in U.S. volumes compared to Q1 2025 [2] - The company raised its full-year 2025 revenue guidance to $1.03–$1.08 billion, up from a previous range of $955 million–$1.025 billion, and adjusted EBITDA guidance increased to $275–$300 million [2] Strategic Initiatives - The results are attributed to the "Indivior Action Agenda," which focuses on expanding SUBLOCADE in the U.S. and improving operational efficiency [3] - Indivior consolidated its stock listing to Nasdaq in July 2025, reinforcing its U.S.-focused growth strategy [3] - Patrick Barry was appointed as Chief Commercial Officer in May, bringing over 30 years of pharmaceutical experience to enhance SUBLOCADE commercialization [3] Future Outlook - Indivior anticipates continued growth for SUBLOCADE through 2026 and beyond, alongside operational improvements aimed at enhancing shareholder value [4] - The company is working towards resolving litigation settlement liabilities by 2027, which is expected to improve financial flexibility [4] - Active research and development efforts are ongoing, with pipeline programs INDV-2000 and INDV-6001 targeting next-generation treatments for OUD and related conditions [4]

Industry Overview - Healthcare spending in the US is projected to reach $5.3 trillion in 2023, making it one of the largest sectors globally [1] - The healthcare industry has shown mediocre returns over the past three years, with a decline of 3.6% in 2022, followed by slight increases of 0.3% in 2023 and 0.9% in 2024 [2] - The healthcare sector is one of four S&P 500 sectors experiencing negative returns in 2025 [2] Regulatory and Political Environment - The underperformance of the healthcare sector in 2025 is attributed to the Trump administration's actions, including pressure for reduced drug pricing and tariffs on pharmaceuticals [3] - Cuts to programs like Medicaid and health research have exacerbated the challenges faced by healthcare organizations [3] - Ongoing political and regulatory uncertainties deter investment interest in the sector [4] Long-term Outlook - Despite recent poor performance, the long-term outlook for the healthcare industry remains favorable due to the essential nature of its goods and services [4] - Many equities in the sector are currently trading at significant discounts, indicating potential investment opportunities [4][5] Investment Strategy - The article emphasizes the importance of hedge fund interest in stocks, suggesting that mimicking top hedge fund picks can lead to market outperformance [8] - A methodology was employed to identify the best-performing healthcare stocks, focusing on those with year-to-date returns of 20% or more and ranked by hedge fund holdings [7] Company Highlights - **Celcuity Inc. (NASDAQ:CELC)**: A clinical-stage biotechnology company focused on oncology therapies, with a lead drug candidate, gedatolisib, recently accepted for NDA by the FDA [10][11] - **ABIVAX Société Anonyme (NASDAQ:ABVX)**: Developing therapies for chronic inflammatory diseases, with positive Phase 3 trial results for its lead candidate, obefazimod, and plans for regulatory submissions in 2026 [13][15][16] - **Indivior PLC (NASDAQ:INDV)**: A pharmaceutical company specializing in opioid use disorder treatments, reporting strong Q2 results with a revenue increase and raised full-year guidance [17][18][19]

Company Overview - Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule allosteric modulators for neurological disorders [3] - The lead drug candidate, dipraglurant, is being evaluated for brain injury recovery, including post-stroke and traumatic brain injury recovery [3] - Addex has a partnership with Indivior for a GABAB PAM drug candidate aimed at substance use disorders, which has completed IND enabling studies [3] - The company is also advancing an independent GABAB PAM program for chronic cough and holds a 20% equity interest in Neurosterix LLC, which is developing allosteric modulator programs for various neurological conditions [3] Recent Developments - Addex Therapeutics announced the appointment of the Bank of New-York Mellon (BNY) as its new ADS depositary agent, effective October 6, 2025 [1] - The appointment of BNY will not impact the fees paid by ADS holders, and no action is required from them at the effective date [2] Stock Information - Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares are listed on the NASDAQ Capital Market under the ticker symbol "ADXN" [3]

Core Viewpoint - Indivior PLC (NASDAQ:INDV) is positioned as a key player in the pharmaceutical industry, focusing on addiction and mental health treatments, particularly opioid addiction, which is a critical public health concern [1][5]. Group 1: Company Overview - Indivior specializes in developing medications for addiction and serious mental health disorders, with a significant emphasis on opioid addiction treatments [1][5]. - The company faces competition from other firms in the addiction treatment sector, including Alkermes and Purdue Pharma [1]. Group 2: Stock Performance and Potential - The target price for INDV is set at $34, indicating a potential growth of 42.65%, suggesting analysts see significant upside potential in the stock [2][4][5]. - Over the past month, INDV has experienced a gain of 3.77%, reflecting a positive trend, although there has been a slight decline of 0.19% in the last 10 days, which may present a buying opportunity [2][4]. Group 3: Financial Health - The Piotroski Score for INDV is 8, indicating strong financial health and solid fundamentals, making it an attractive option for value investors [3][5]. - The high Piotroski Score suggests that INDV is well-positioned financially, which is a positive indicator for potential investors [3].

Core Insights - Indivior has moved up 11 positions to the 46th spot on Barchart's Top 100 Stocks to Buy, indicating strong market interest and momentum [1] - The company has shown significant growth, with a nearly 13% increase in stock price over the past month and a remarkable 139% increase over the past 12 months [1] Financial Performance - In the first half of 2025, Indivior reported a net profit of $65 million, a 281% increase compared to a loss of $36 million in the same period the previous year [4] - On a non-GAAP basis, earnings were $121 million, down from $138 million, primarily due to previous litigation expenses [4][5] - For the full year 2025, Indivior expects top-line revenue of $1.055 billion, an increase from the previous estimate of $990 million, although down from $1.18 billion in 2024 [6] - The company anticipates adjusted EBITDA of $288 million for 2025, up from a prior estimate of $240 million [7] Product and Market Dynamics - Indivior's revenue is heavily reliant on its Sublocade product, which accounts for 70% of annual revenue, with the U.S. market contributing 93% of Sublocade revenue [8] - Despite increased competition leading to a decline in market share for its Suboxone products, Sublocade revenue is expected to rise by 3% in 2025, reaching $775 million [6]

Core Insights - The session is part of the Morgan Stanley Global Healthcare Conference, featuring key executives from Indivior, including CEO Joe Ciaffoni and CFO Ryan Preblick [2]. Group 1 - The session is introduced by Thibault Boutherin, co-head of the European Pharm Equity Research team based in London [1]. - Important disclosures related to the session can be found on the Morgan Stanley website [2]. - The format of the session includes introductory remarks followed by a Q&A segment [3].

Summary of Indivior Conference Call Company Overview - **Company**: Indivior - **Industry**: Pharmaceutical, specifically focused on treatments for opioid use disorder Key Points and Arguments Financial Performance and Guidance - Indivior is optimistic about its performance in 2025 and is focused on executing its financial guidance despite acknowledging the challenges ahead [2][4] - The company is generating significant revenue and has a strong growth driver in SUBLOCADE, which is the first long-acting injectable for opioid use disorder [11][12] - Indivior plans to reduce operational expenses significantly starting January 2026, with a focus on eliminating non-essential activities while investing heavily in SUBLOCADE [17][18][50] Indivior Action Agenda - The company is currently in phase one of its Indivior Action Agenda, aimed at generating momentum for SUBLOCADE through improved commercial execution [3][21] - Phase two, expected to start on January 1, 2026, will focus on accelerating SUBLOCADE's market penetration, particularly in the U.S. [4][21] Medicaid and Revenue Sources - Over half of Indivior's revenue comes from Medicaid, with approximately 65% of SUBLOCADE's revenue derived from this source [9][10] - The company is confident in its ability to grow SUBLOCADE within the Medicaid framework, especially given recent legislative support for opioid use disorder treatments [9][10] Market Position and Competition - SUBLOCADE is the number one prescribed long-acting injectable and has been used in over 350,000 patients, with 88% coverage in Medicare and Medicaid [22][23] - Indivior acknowledges competition from products like Brixadi but remains confident in SUBLOCADE's market position and its unique attributes [23][24] Long-Acting Injectable Market - Current penetration of long-acting injectables in the buprenorphine market is around 8%, with aspirations to increase this significantly through education and marketing efforts [25][27] - The company recognizes various barriers to increasing penetration, including patient preferences and physician inertia, and is focused on addressing these challenges [28][29] Strategic Focus and Future Plans - Indivior is committed to enhancing its commercial execution and is exploring options for its international operations, which currently contribute 15% of sales [19][20] - The company is also evaluating its pipeline, with two Phase 2 assets under consideration for potential advancement to Phase 3 [42][44] Capital Allocation and Shareholder Value - Indivior plans to reassess its capital allocation priorities in early 2026, focusing on executing its current operational strategies before considering M&A or returning cash to shareholders [46][48] - The CEO believes there is a significant gap between the intrinsic value of the company and its current stock price, attributing this to market misunderstandings regarding SUBLOCADE's growth potential and the company's cost structure [49][50] Additional Important Insights - Indivior's workforce is highly motivated, with over 85% of employees personally impacted by substance use disorder, contributing to the company's resilience [12] - The company is actively working to improve its organizational complexity and streamline operations to better focus on its core products [14][15] This summary encapsulates the key insights from the Indivior conference call, highlighting the company's strategic direction, market positioning, and financial outlook.

Company Participation in Investor Events - Indivior PLC will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8th, where CEO Joe Ciaffoni and CFO Ryan Preblick will host meetings and a fireside discussion [1] - The company will also attend the H.C. Wainwright 27th Annual Global Investment Conference on September 9th, with similar meeting arrangements [2] Company Overview - Indivior is a global pharmaceutical company focused on developing medicines for opioid use disorder (OUD), aiming to transform OUD into a recognized chronic disease [3] - The company is headquartered in Richmond, VA, employs over 1,000 individuals globally, and its products are available in over 30 countries [3]

Core Insights - Indivior PLC has established itself as a leader in long-acting injectable treatments for opioid use disorder, showcasing significant growth in its product SUBLOCADE [1] - The company's Q2 2025 results indicate strong performance, characterized by increasing cash flows and a strategic focus on a three-phase development plan [1] Company Performance - The Q2 2025 results highlight robust growth in SUBLOCADE, which is a key product for the company [1] - There is a notable increase in cash flows, suggesting improved financial health and operational efficiency [1] Industry Position - Indivior PLC is positioned as a science-based expert in the treatment of opioid use disorder, indicating a strong competitive advantage in the healthcare sector [1]

Core Viewpoint - Indivior PLC (INDV) has been upgraded to a Zacks Rank 1 (Strong Buy), indicating a positive earnings outlook that may lead to increased stock price [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in earnings estimates, which are a significant factor influencing stock prices [4][6]. - Rising earnings estimates for Indivior suggest an improvement in the company's underlying business, likely resulting in upward pressure on its stock price [5][10]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [7]. - Only the top 5% of Zacks-covered stocks receive a "Strong Buy" rating, indicating superior earnings estimate revisions [9][10]. Recent Earnings Estimate Revisions - Indivior is expected to earn $1.45 per share for the fiscal year ending December 2025, with no year-over-year change [8]. - Over the past three months, the Zacks Consensus Estimate for Indivior has increased by 22.9%, reflecting positive sentiment among analysts [8].